Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363373 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL840939 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL14304968 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL12000798 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL295573 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL23845860 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL137622 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL723342 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL13460643 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL13460354 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4540374-A1 | SURFACE CALR CHEMICAL INDUCERS | The Children's Medical Center Corporation (US) | 2025-04-23 | — | — | EP | claimed |
| WO-2023244470-A1 | SURFACE CALR CHEMICAL INDUCERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-12-21 | — | — | WO | claimed |
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4540374-A1 | SURFACE CALR CHEMICAL INDUCERS | The Children's Medical Center Corporation (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025030019-A1 | TARGETING TLR3 FOR TREATMENT OF HEMATOPOIETIC STEM CELL PROLIFERATION-ASSOCIATED DISEASES OR DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025017212-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024211811-A2 | METHODS AND COMPOSITIONS FOR ANTIBODY-DRUG CONJUGATES | FREZENT BIOLOGICAL SOLUTIONS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2023244470-A1 | SURFACE CALR CHEMICAL INDUCERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-8304447-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304447-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GENZYME CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GENZYME CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20070185176-A1 | Heparanase inhibitors and uses thereof | INSIGHT BIOHARMACEUTICALS LTD. (IL) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185176-A1 | Heparanase inhibitors and uses thereof | HPSE, ENGASE, HEXA | UGCG 129/4885KMT2A 2842/4885MEN1 2391/4885 |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GBA1, GBA2, ASAH2 | UGCG 14/4885KMT2A 1338/4885MEN1 2201/4885 |
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | ASAH2, GBA1, GAA | UGCG 6/4885KMT2A 1937/4885MEN1 3973/4885 |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GBA1, UGCG, GBA2 | UGCG 2/4885KMT2A 3993/4885MEN1 1648/4885 |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | UGCG 6/4885KMT2A 1937/4885MEN1 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.